Evidence map›Paper›PMID 41057667›Full record

ArticleCancer gene therapy2025

Unveiling the role of the extracellular matrix in the osteosarcoma tumor microenvironment through integrated transcriptomics and experimental validation.

Yuyang Liu, Yuchen Han, Zixuan Guo, Yinglong Zhang, Xiuyuan Xu, Wenting Qi, Meng Xu, Jianxiong Li

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuyang Liu *Senior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Yuchen Han *Senior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Zixuan Guo *Senior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Yinglong ZhangSenior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Xiuyuan XuKunming Medical University, Kunming, Yunnan, China.
Wenting QiDepartment of Internal medicine, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. qiwenting2012@126.com.
Meng XuSenior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China. 13501175839@163.com.
Jianxiong LiSenior Department of Orthopedics, Chinese PLA General Hospital, Beijing, China. lijianxiong@301hospital.com.cn.ORCID 0000-0002-1675-7003

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82002842National Natural Science Foundation of China (National Science Foundation of China) 82403886
6 · The paper itself

Abstract

Osteosarcoma (OS), the most common malignant bone tumor, is characterized by heterogeneous tumor cells and abundant microenvironmental components. The extracellular matrix (ECM)-a complex and dynamic network surrounding tumor cells-plays a pivotal role in OS malignancy (e.g., cell proliferation, metastasis), making insights into ECM involvement critical for advancing OS prognosis. This study conducted bioinformatic analyses on bulk RNA-sequencing and single-cell RNA sequencing data from public databases, initially identifying collagen type V alpha 2 (COL5A2) as a key gene in OS progression. It further validated biological functions and underlying mechanisms of COL5A2 via in vitro experiments, and constructed and validated prognostic models based on ECM signature cell clusters. Results identified osteoblastic cells (OCs) and endothelial cells (ECs) as core cellular components of OS. COL5A2 was highly expressed in OCs, and high COL5A2 expression correlated with significantly reduced overall survival in OS patients. Western blot, CCK-8, and colony formation assays demonstrated that COL5A2 promoted OS cell proliferation by activating the focal adhesion pathway and inducing phosphorylation of the FAK/Paxillin/Akt signaling axis. The prognostic model highlighted the C0 OCs cluster as clinically significant. CellChat analysis uncovered significant activation of the IGFBP pathway in both C0 OCs and C1 ECs, and identified the IGFBP3-TMEM219 axis as the key ligand-receptor pair mediating their crosstalk. This study establishes COL5A2 and the C0 OCs cluster as pivotal ECM-related signatures in OS, confirming COL5A2 drives OS proliferation through focal adhesion signaling and IGFBP3-TMEM219-mediated crosstalk-both representing promising therapeutic targets. Further investigation into ECM components is warranted to refine OS treatment strategies and improve clinical outcomes.

Indexed as

Bone NeoplasmsCollagen Type VExtracellular MatrixOsteosarcomaTranscriptomeTumor MicroenvironmentCell Line, TumorCell ProliferationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisCollagen Type V

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.